Acrux Limited (AU:ACR) has released an update.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Acrux Limited has achieved FDA approval for its sixth topical ANDA, a generic version of Nitroglycerin Ointment, aimed at treating pain from chronic anal fissures. This approval marks another milestone for Acrux’s R&D team, highlighting their ability to develop and commercialize topical pharmaceutical products. With an annual market exceeding $23 million in sales, Acrux’s new product is set to compete in the growing US market.
For further insights into AU:ACR stock, check out TipRanks’ Stock Analysis page.
